Bioresorbable scaffolds for percutaneous coronary interventions

Global Cardiology Science and Practice

Volumn 2014, Issue 4, 2014, Pages

  Gogas, Bill D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioresorbable scaffolds; Coronary revascularization; Invasive multimodality imaging

Indexed keywords

ESTER DERIVATIVE; MAGNESIUM; POLY(ANHYDRIDE ESTER); POLYLACTIC ACID; SALICYLIC ACID; TYROSINE; UNCLASSIFIED DRUG;

ABSORBABLE MAGNESIUM STENT; ARTICLE; ATHEROSCLEROSIS; BARE METAL STENT; BIOLOGICAL MODEL; BIOMEDICAL ENGINEERING; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR STENT; BLOOD VESSEL FUNCTION; CLINICAL EFFECTIVENESS; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; CORONARY HEMODYNAMICS; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DEVICE SAFETY; DRUG ELUTING STENT; HEALTH CARE POLICY; HEART MUSCLE ISCHEMIA; HUMAN; INTERVENTION STUDY; METAL STENT; MULTICENTER STUDY (TOPIC); NEOATHEROSCLEROSIS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL CHEMISTRY; SWINE;

EID: 85111309877     PISSN: None     EISSN: 23057823     Source Type: Journal    
DOI: 10.5339/gcsp.2014.55     Document Type: Article

References (62)

1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. Feb 4 1978; 1(8058):263.
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. The New England journal of medicine. Aug 25 1994; 331(8):489-495.
3. Farooq V, Gogas BD, Serruys PW. Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv. Apr 1 2011; 4(2):195-205.
4. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. Jul 4 2006; 48(1):193-202.
5. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. Mar 20 2007; 115(11):1440-1455; discussion 1455.
6. Palmerini T, Biondi-Zoccai G, Delia Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. Apr 14 2012; 379(9824):1393-1402.
7. Finn AV, Nakazawa G, Joner M., et al. Vascular responses to drug eluting stents: importance of delayed healing. Arteriosclerosis, thrombosis, and vascular biology. Jul 2007; 27(7):1500-1510.
8. Raber L, Magro M, Stefanini G.G., et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. Mar 6 2012; 125(9):1110-1121.
9. Garg S, Serruys PW. Coronary stents: looking forward. Journal of the American College of Cardiology. Aug 31 2010; 56(10 Suppl):S43-78.
10. Pendyala LK, Yin X, Li J., Chen JP, Chronos N, Hou D. The first-generation drug-eluting stents and coronary endothelial dysfunction. JACC. Cardiovascular interventions. Dec 2009; 2(12):1169-1177.
11. Obata JE, Kitta Y, Takano H., et al. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. Journal of the American College of Cardiology. Oct 2 2007; 50(14):1305-1309.
12. Park SJ, Kang SJ, Virmani R, Nakano M., Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. Journal of the American College of Cardiology. Jun 5 2012; 59(23):2051-2057.
13. Serruys PW, Garg S, Abizaid A., et al. A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. Eurointervention: journal of Euro PCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Jun 2010; 6(2): 195-205.
14. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. Sep 27 2008; 372(9644):1163-1173.
15. Serruys PW, Farooq V, Kalesan B., et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC. Cardiovascular interventions. Aug 2013; 6(8):777-789.
16. Gogas BD, McDaniel M, Samady H., King SB, 3rd. Novel drug-eluting stents for coronary revascularization. Trends in cardiovascular medicine. Oct 2014; 24(7):305-313.
17. Wykrzykowska JJ, Onuma Y, Serruys PW. Vascular restoration therapy: the fourth revolution in interventional cardiology and the ultimate "rosy" prophecy. Eurointervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Dec 15 2009; 5 Suppl F: F7-8.
18. van der Giessen WJ, Lincoff AM, Schwartz R.S., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. Oct 1 1996; 94(7): 1690-1697.
19. Koskinas KC, Chatzizisis YS, Antoniadis A.P., Giannoglou GD. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. Journal of the American College of Cardiology. Apr 10 2012; 59(15):1337-1349.
20. Thury A, Wentzel JJ, Vinke R.V., et al. Images in cardiovascular medicine. Focal in-stent restenosis near step-up: roles of low and oscillating shear stress? Circulation. Jun 11 2002; 105(23):e185-187.
21. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. Circulation. Nov 1983; 68(5):951-960.
22. Van der Heiden K, Gijsen FJ, Narracott A, et al. The effects of stenting on shear stress: relevance to endothelial injury and repair. Cardiovascular research. Jul 15 2013; 99(2):269-275.
23. Brugaletta S, Heo JH, Garcia-Garcia HM, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? European heart journal. Jun 2012; 33(11):1325-1333.
24. Hahn C, Schwartz MA. Mechanotransduction in vascular physiology and atherogenesis. Nature reviews. Molecular cell biology. Jan 2009; 10(1):53-62.
25. Sarno G, Lagerqvist B, Frobert O., et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. Mar 2012; 33(5):606-613.
26. Brugaletta S, Radu MD, Garcia-Garcia HM, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis. Mar 2012; 221(1):106-112.
27. Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. Eurointervention. Dec 15 2009; 5 Suppl F: F15-22.
28. Gopferich A. Mechanisms of polymer degradation and erosion. Biomaterials. Jan 1996; 17(2):103-114.
29. Vorpahl M, Finn AV, Nakano M, Virmani R. The bioabsorption process: tissue and cellular mechanisms and outcomes. Eurointervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Dec 15 2009; 5 Suppl F: F28-35.
30. Gogas BD, Farooq V, Onuma Y., Serruys PW. The ABSORB bioresorbable vascular scaffold: an evolution or revolution in interventional cardiology? Hellenic J Cardiol. Jul-Aug 2012; 53(4):301-309.
31. Onuma Y, Serruys PW, Perkins L.E., et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. Nov 30 2010; 122(22):2288-2300.
32. Gogas BD, Radu M, Onuma Y., et al. Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies. Int J Cardiovasc Imaging. Mar 2012; 28(3):499-511.
33. Tamai H, Igaki K, Kyo E., et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. Jul 25 2000; 102(4):399-404.
34. Nishio S, Kosuga K, Igaki K., et al. Long-Term (>10 Years) clinical outcomes of first-inhuman biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation. May 15 2012; 125(19):2343-2353.
35. Heublein B, Rohde R, Kaese V., Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart. Jun 2003; 89(6):651-656.
36. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. Jun 2 2007; 369(9576):1869-1875.
37. Haude M, Erbel R, Erne P., et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet. Mar 9 2013; 381(9869):836-844.
38. Grube E, Sonoda S, Ikeno F., et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation. May 11 2004; 109(18):2168-2171.
39. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. Mar 15 2008; 371(9616):899-907.
40. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. Mar 14 2009; 373(9667):897-910.
41. Ormiston JA, Serruys PW, Onuma Y, et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv. Oct 2012; 5(5):620-632.
42. Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. Eurointervention. Dec 3 2013.
43. Gomez-Lara J, Garcia-Garcia HM, Onuma Y., et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC. Cardiovascular interventions. Nov 2010; 3(11):1190-1198.
44. Gogas BD, Bourantas CV, Garcia-Garcia HM, et al. The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials. Eurointervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Oct 22 2013; 9(6):709-720.
45. Gogas BD, Garcia-Garcia HM, Onuma Y., et al. Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds. JACC. Cardiovascular interventions. Mar 2013; 6(3):211-221.
46. Verheye S, Ormiston JA, Stewart J, et al. A Next-Generation Bioresorbable Coronary Scaffold System-From Bench to First Clinical Evaluation: Six- and 12-Month Clinical and Multimodality Imaging Results. JACC Cardiovasc Interv. Oct 10 2013.
47. Jabara R, Chronos N, Robinson K. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. Catheter Cardiovasc Interv. Aug 1 2008; 72(2):186-194.
48. Jabara R, Pendyala L, Geva S., Chen J, Chronos N, Robinson K. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. Eurointervention. Dec 15 2009; 5 Suppl F: F58-64.
49. Zeltinger J. Bio-Mechanical properties & ABC of Tyrosine polycarbonate. PCR FOCUS GROUP 2012. Oral presentation
50. Lafont A, Durand E. A.R.T.: concept of a bioresorbable stent without drug elution. Eurointervention. Dec 15 2009; 5 Suppl F: F83-87.
51. Waksman R, Prati F, Bruining N., et al. Serial observation of drug-eluting absorbable metal scaffold: multi-imaging modality assessment. Circ Cardiovasc Interv. Dec 1 2013; 6(6):644-653.
52. Serruys PW, Onuma Y, Dudek D., et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. Journal of the American College of Cardiology. Oct 4 2011; 58(15): 1578-1588.
53. Gogas BD, Yang B, Passerini T., et al. Computational Fluid Dynamics Applied to Virtually Deployed Drug-Eluting Coronary Bioresorbable Scaffolds. Clinical Translations Derived from a Proof-of-Concept. GCSP. Dec.
54. Nieman K, Serruys PW, Onuma Y, et al. Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). J Am Coll Cardiol. Nov 5 2013; 62(19): 1813-1814.
55. Kastrati A, Mehilli J, Dirschinger J., et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. Jun 12 2001; 103(23):2816-2821.
56. Pache J, Kastrati A, Mehilli J., et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. Apr 16 2003; 41(8):1283-1288.
57. Muramatsu T, Onuma Y, Garcia-Garcia HM, et al. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv. Mar 2013; 6(3):247-257.
58. Farooq V, Serruys PW, Heo J.H., et al. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. JACC. Cardiovascular interventions. May 2013; 6(5):523-532.
59. Ormiston JA, De Vroey F, Serruys PW, Webster MW. Bioresorbable polymeric vascular scaffolds: a cautionary tale. Circ Cardiovasc Interv. Oct 1 2011; 4(5):535-538.
60. Farooq V, Gomez-Lara J, Brugaletta S., et al. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study. Catheter Cardiovasc Interv. May 1 2012; 79(6):880-888.
61. Ryan J, Cohen DJ. Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation. Oct 17 2006; 114(16):1736-1743; discussion 1744.
62. Schafer PE, Sacrinty MT, Cohen D.J., et al. Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice. Circ Cardiovasc Qual Outcomes. Jul 2011; 4(4):408-415.